Details

Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment
ID Koceva, Andrijana (Author), ID Janež, Andrej (Author), ID Jensterle Sever, Mojca (Author)

.pdfPDF - Presentation file, Download (1,45 MB)
MD5: ACC03FAF4F6A7F57B7A1F865761D2EC8
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/abs/pii/S1521690X25000715 This link opens in a new window

Abstract
Obesity is rising among women of reproductive age and significantly contributes to subfertility. If conception occurs, maternal obesity is associated with increased risks for both maternal and neonatal complications, with potential long-term effects on the offspring's health. Current clinical guidelines emphasize the importance of preconception weight optimization in women with obesity to reduce maternal and fetal risks. Amid the rising use of incretin-based anti-obesity medications, particularly among young women, their potential role in preconception care is receiving growing clinical and research interest. With unplanned pregnancies remaining common, incidental exposure during early pregnancy is becoming more likely. In parallel, there is increasing interest in the potential of these agents to support preconception weight loss and enhance fertility outcomes in women with obesity. This narrative review examines the current human evidence on GLP-1 and dual GLP-1/GIP receptor agonists approved for obesity treatment, focusing on their potential role in preconception care and addressing key safety considerations and challenges related to their use during the preconception period, as well as inadvertent exposure in early pregnancy.

Language:English
Keywords:GLP-1 receptor agonist, GLP-1/GIP receptor agonist, preconception care, liraglutide, semaglutide, tirzepatide
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:10 str.
Numbering:Vol. 39, iss. 6, art. 102038
PID:20.500.12556/RUL-182728 This link opens in a new window
UDC:616.4
ISSN on article:1521-690X
DOI:10.1016/j.beem.2025.102038 This link opens in a new window
COBISS.SI-ID:250744067 This link opens in a new window
Publication date in RUL:21.05.2026
Views:263
Downloads:231
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Baillière's best practice & research. Clinical endocrinology and metabolism
Shortened title:Baillière's best pract. res. Clin. endocrinol. metab.
Publisher:Elsevier
ISSN:1521-690X
COBISS.SI-ID:2071060 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:agonist receptorja GLP-1, agonist receptorja GLP-1/GIP, predzanositvena oskrba

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back